Research Analysts Set Expectations for EWTX Q3 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Stock analysts at HC Wainwright cut their Q3 2026 EPS estimates for shares of Edgewise Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst L. Egana-Gorrono now anticipates that the company will earn ($0.53) per share for the quarter, down from their prior estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q4 2026 earnings at ($0.55) EPS, FY2026 earnings at ($2.07) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($2.15) EPS and FY2029 earnings at ($1.24) EPS.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.06).

Several other research analysts have also weighed in on the company. Truist Financial set a $52.00 price objective on Edgewise Therapeutics in a research report on Wednesday, May 6th. Leerink Partners set a $52.00 target price on Edgewise Therapeutics in a research report on Tuesday, June 16th. Royal Bank Of Canada raised their target price on Edgewise Therapeutics from $48.00 to $59.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 17th. Raymond James Financial reiterated a “strong-buy” rating and issued a $66.00 target price on shares of Edgewise Therapeutics in a report on Monday, June 1st. Finally, The Goldman Sachs Group boosted their price target on Edgewise Therapeutics from $32.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $49.08.

Edgewise Therapeutics Trading Down 0.6%

Shares of EWTX opened at $44.31 on Monday. The stock has a market capitalization of $4.81 billion, a P/E ratio of -23.95 and a beta of 0.30. The firm’s fifty day simple moving average is $39.68 and its two-hundred day simple moving average is $34.35. Edgewise Therapeutics has a 12 month low of $12.84 and a 12 month high of $48.40.

Insider Activity

In other news, insider Alan J. Russell sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $39.41, for a total value of $7,882,000.00. Following the completion of the sale, the insider directly owned 24,555 shares in the company, valued at $967,712.55. This trade represents a 89.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 21.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edgewise Therapeutics

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Edgewise Therapeutics in the 2nd quarter worth $268,415,000. Deutsche Bank AG bought a new stake in Edgewise Therapeutics during the 2nd quarter valued at $9,954,000. Persistent Asset Partners Ltd acquired a new position in Edgewise Therapeutics during the second quarter worth $2,821,000. Bank of New York Mellon Corp bought a new position in shares of Edgewise Therapeutics in the second quarter valued at $8,628,000. Finally, State of Wyoming acquired a new position in shares of Edgewise Therapeutics during the second quarter valued at about $525,000.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.